Buyer Access · healthcareJul 202610 min read332 words

Buyer clubs and executive access for Series B companies: scaling without breaking for healthcare and life sciences

How Series B companies scale buyer clubs and executive access across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies.

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install buyer clubs and executive access has to reflect that reality from day one.

Series B is the stress test for buyer clubs and executive access. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, cycle length from first touch to closed-won, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Buyer clubs and executive access is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of buyer clubs and executive access is confusing sponsorship with membership, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on cycle length from first touch to closed-won outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run buyer clubs and executive access function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing buyer clubs and executive access properly rather than half-heartedly across three vendors.

buyer clubsexecutive accessCXO networksbuyer clubs for series Bscaling GTMbuyer clubs for healthcare and life scienceshealthcare buyer clubshealthcare and life sciences growth

Frequently asked questions

Buyer Access · healthcare — answered

Does buyer clubs and executive access work for healthcare and life sciences?
Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
How does buyer clubs and executive access change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible cycle length from first touch to closed-won.
What compensation model works for buyer clubs and executive access operators at Series B?
Outcome-linked on cycle length from first touch to closed-won, not activity-based.
What is the Series B stress point?
Confusing sponsorship with membership, amplified by headcount. Fix the root, not the symptom.
What is the healthcare specific pitfall with buyer clubs and executive access?
Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.

Growth Broker editorial

Filed under buyer access · healthcare

Up next

Buyer clubs and executive access trends to watch in 2026 for healthcare and life sciences

Read piece

Ready to broker your growth?

Book a Growth Call